Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Other financing activities: 2019-2025

Historic Other financing activities for BridgeBio Pharma (BBIO) over the last 5 years, with Sep 2025 value amounting to -$10.5 million.

  • BridgeBio Pharma's Other financing activities rose 34.42% to -$10.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.7 million, marking a year-over-year increase of 476.91%. This contributed to the annual value of $16.0 million for FY2024, which is N/A change from last year.
  • As of Q3 2025, BridgeBio Pharma's Other financing activities stood at -$10.5 million, which was down 246.45% from $7.2 million recorded in Q2 2025.
  • Over the past 5 years, BridgeBio Pharma's Other financing activities peaked at $16.1 million during Q1 2021, and registered a low of -$16.0 million during Q3 2024.
  • In the last 3 years, BridgeBio Pharma's Other financing activities had a median value of $3.7 million in 2023 and averaged $2.5 million.
  • The largest annual percentage gain for BridgeBio Pharma's Other financing activities in the last 5 years was 412.77% (2023), contrasted with its biggest fall of 865.60% (2023).
  • Over the past 5 years, BridgeBio Pharma's Other financing activities (Quarterly) stood at $734,000 in 2021, then decreased by 18.80% to -$283,000 in 2022, then tumbled by 865.60% to -$4.6 million in 2023, then tumbled by 250.34% to $16.0 million in 2024, then spiked by 34.42% to -$10.5 million in 2025.
  • Its Other financing activities stands at -$10.5 million for Q3 2025, versus $7.2 million for Q2 2025 and $12.0 million for Q1 2025.